KRAS G12C Inhibitor

Adagrasib (MRTX849)

Adagrasib is an investigational highly selective and potent oral small molecule therapy designed to treat some of the most complex and aggressive cancers.

Adagrasib (MRTX849)

Adagrasib is an investigational highly selective and potent oral small molecule therapy designed to treat some of the most complex and aggressive cancers.

Mechanism of Action

Mirati is developing the investigational drug candidate adagrasib, to target KRAS G12C and maximize inhibition by irreversibly locking the mutant protein in its inactive state.

Preclinical studies of adagrasib demonstrated key characteristics including:

Potent

Low nanomolar potency across multiple cellular models of KRAS G12C10

Long half-life

Only KRAS G12C inhibitor with a ~ 24-hour half-life10

Highly selective

1,000+ fold selective for mutant KRAS G12C vs wild-type KRAS and other protein cysteines10

Wide therapeutic index

Preclinical projection of >10-fold safety margin10

Extensive tissue distribution

Only KRAS inhibitor where projected human volume of distribution exceeds 10L/kg10

Watch our mechanism of action video

Program Summary

Adagrasib is being explored as a monotherapy as well as in combination with other anticancer drugs. The goal is to optimize efficacy and prevent treatment resistance, ensuring these potentially promising combination therapies can help patients throughout the course of their treatment journey.

Extensive preclinical studies showed that combining adagrasib with a broad range of therapies, including PD-1, SHP2, Pan-EGFR, CDK 4/6, and SOS1 inhibitors, resulted in even more robust anti-tumor activity.

Adagrasib (MRTX849) Combination Therapy